Related Experiment Video
Updated: Jun 14, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[FLT3 gene mutation and its prognostic implication in patients with acute leukemia.]
Objective:
To evaluate the prevalence of FLT3 mutation in different subtypes of acute leukemia (AL) patients diagnosed by WHO criteria and its significance in prognosis.
Methods:
Polymerase chain reaction (PCR) was used to detect internal tandem duplication of FLT3 gene (FLT3-ITD) and D835 mutation in 468 firstly diagnosed AL patients and analyzed their prognosis by Kaplan-Meier and log-rank test.
Results:
In 468 AL patients, there were 374 acute myeloid leukemia (AML) cases (79.9%) and 83 acute lymphoblastic leukemia (ALL) cases (17.7%). In AML patients, FLT3-ITD mutation was present in 59 cases (15.9%) while D835 mutation in 15 cases (4.0%); and in ALL patients, none for FLT3-ITD while D835 mutation in 2 cases (2.4%). FLT3-ITD mutation might adversely affect clinical outcome in AML patients (excluding APL) with a lower CR rate (52.3% vs 71.2%) and a shorter median survival (9 months vs 18 months). For APL FLT3-ITD mutation had no effect on CR rate, but with a shorter DFS and OS. There was no evidence that FLT3-D835 affected the prognosis.
Conclusion:
FLT3 mutation is more frequently present in AML and FLT3-ITD is associated with lower CR rate and shorter median survival time while FLT3-D835 has no such effect.
